Epigenetics
Drugs and Diagnostic Technologies Market was valued at USD 1.6
billion in 2013 and is estimated to reach a market worth USD 5.7
billion in 2019 at a CAGR of 19.4% from 2013 to 2019.
Browse
the full report at
http://www.transparencymarketresearch.com/epigenetics-market.html
The
growth of the epigenetics market is driven by factors such as
increase in aging population, as there is a strong correlation
between cancer and aging. According to WHO, it is estimated that
global population over the age of 60 years would double from 11%
(2000) to 22% (2050). People aged 60 and above are more prone to
cancer. Hence, countries are advocating early detection of cancer
through screening kits (Epi Procolon, Epi ProLung) which are driving
the epigenetic drugs and diagnostic technologies market.
Epigenetic
drugs make it possible to reverse the aberrant gene expression which
leads to various disease states. The inhibitors, DNA
methyltransferase (DNMT) and Histone Deacetylase (HDAC) are
responsible for regulating the cellular expression. Out of the two
inhibitors, DNMT accounts for a larger share as these inhibitors
offer an improved access for targeting the cancerous cells.
Currently, four drugs are approved by FDA and are commercially
available. Two of them are DNMT inhibitors: Celgene's Vidaza
(azacitidine) and Eisai's Dacogen (decitabine) for the treatment of
Myelodysplastic Syndrome (MDS), and the other two are HDAC
inhibitors: Merck's Zolinza (vorinostat) and Celgene's Istodax
(romidepsin) both for treatment of Cutaneous T Cell Lymphoma (CTCL).
Epigenetics
is a rapidly developing field not only in oncology but also in
non-oncology indications (Alzheimer's and arthritis). Due to the
increase in disease identification, manufacturers are taking
initiatives in development of varied epigenetic diagnostic
techniques. DNA methylation technique in the diagnostic segment
accounts for the largest share as compared to histone modification
techniques, as the research on DNA methylation has been carried out
since decades, and is thus mostly preferred. Furthermore, with the
corresponding advancements in research and technology, histone code
hypothesis technique came into existence only in late 1980s. Hence,
with the surge in interest, there is also an increase in investment
for the research and development of histone modifications.
North
America accounts for the largest share of the epigenetics market. It
is expected that North America will dominate around half of the
global epigenetics market due to increasing incidence of cancer and
other non-oncology indications. Oncology and other non-oncology
indications (Alzheimer's and arthritis) are associated with
epigenetics; thus the increasing incidence of cancer supports the
growth of the epigenetics market. Asia accounts for nearly half of
the new cancer cases worldwide. The rising incidence of cancer cases
in the Asian region would boost the demand for epigenetic drugs and
diagnostic technologies in this market. Australia, China, Japan and
South Korea are the largest markets for these therapies. Japan
dominates the epigenetics market in Asia-Pacific due to a significant
presence of companies in the therapeutics segment such as Eisai
Pharmaceuticals and Oncolys Biopharma. These companies are taking
initiatives for the development and commercialization of epigenetic
drugs. Various research institutes and investments from these
companies would drive the epigenetics market.
Some
of the key players in this market include Celgene Corporation, Merck,
Eisai Pharmaceuticals, Exact Sciences, Epigenomics and others.
Manufacturers are entering into strategic alliances with numerous
research institutions and other players for the development and
commercialization of new and innovative drugs, which might see new
players in the market looking to carve out a share of the market for
themselves.
The
epigenetics drugs and diagnostic technologies market is segmented as
follows:
Epigenetics Drugs Market, by Mechanism of Action
DNMT Inhibitors
Epigenetics Diagnostic Technologies Market, by Types
DNA Methylation
Chromatin Immunoprecipitation (ChIP) Technology
Epigenetics Technologies Market, by Geography
North America
Europe
Asia-Pacific
RoW
For Sample Report Visit On:
About Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. We are
privileged with highly experienced team of Analysts, Researchers, and
Consultants, who use proprietary data sources and various tools and
techniques to gather, and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
No comments:
Post a Comment